Zoetis Inc. (ZTS) Earnings Call Transcripts
Zoetis Inc.'s Latest Earnings Call - June 2, 2026
In the Q1 2026 earnings call, Zoetis Inc. reported revenues of $2.3 billion, reflecting a 3% decline year-over-year, which was below analyst expectations. Earnings per share (EPS) came in at $0.75, missing estimates by $0.10. Management highlighted ongoing macroeconomic challenges impacting consumer behavior in the companion animal segment, particularly in clinic visits and dosage intervals, while maintaining a long-term growth outlook driven by innovation and a strong livestock market. Guidance for the full year remains cautious, with expectations for mid-single-digit growth in livestock and continued investment in R&D and share buybacks.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $2.3B (miss) |
| EPS | $0.75 (miss) |
| Livestock Growth Rate | Mid-single-digit to high-single-digit (positive) |
| Clinic Visit Decline | -2% (negative) |
| Free Cash Flow | $2.3B (positive) |
| Remaining Share Buyback Authorization | $1.8B (positive) |
Guidance from management
Management maintained a cautious outlook for 2026, expecting mid-single-digit growth in livestock and continued challenges in the companion animal segment due to macroeconomic pressures.
What analysts pressed on
Analysts expressed concerns over the declining clinic visits and the impact of increased competition in therapeutic categories. There were questions regarding the sustainability of growth in the companion animal market amidst these challenges.
Main topics on the call
- Macro Challenges — Management noted that 'the cumulative effect of price increases' is leading to a decline in clinic visits, which were down about 2% in the quarter. This trend is compounded by increased competition in therapeutic categor...
- Innovation Pipeline — Zoetis emphasized its strong innovation pipeline, with 12 potential blockbusters in development. The company expects significant contributions from upcoming products like long-acting Cytopoint and renal therapies, which ...
- Livestock Growth — The livestock segment showed robust growth, with management projecting mid-single-digit to high-single-digit growth for the year. This is supported by strong demand for animal protein and effective vaccines, particularly...
- Consumer Spending Trends — Despite macro pressures, management noted that 'pet owners remain engaged in the care of their pets,' with spending on diagnostics and emergency care continuing to perform well. This indicates a resilient long-term deman...
Read the full Zoetis Inc. transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Zoetis Inc.
Zoetis Inc. (ZTS) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 77 calls on record spanning January 15, 2020 to June 2, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 77 Zoetis Inc. earnings call transcripts on record, spanning January 15, 2020 to June 2, 2026. Based on this history, Zoetis Inc. reports quarterly. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ZTS
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 77
- First call
- January 15, 2020
- Most recent
- June 2, 2026
- Reporting cadence
- quarterly